CompChem Solutions now has access to BioSolveIT’s infiniSee xREAL tools to query the Enamine REAL space using fingerprint and “fuzzy pharmacophore” approaches. Your IP will remain private using our locally-installed software. We can use the system to identify synthesisable and purchasable analogues of your hit or lead compounds across literally trillions of accessible compounds. Contact us for more information.
CompChem Solutions now has generative AI tools up and ready for use to help identify alternative chemical moieties for hit expansion, lead expansion, lead optimisation or scaffold hopping. Contact us for more information.
New work in collaboration with Cancer Research Horizons/CRUK on “Scalable Synthesis of an Acid Stable Analogue of Hippuristanol” has been published in Organic Letters: MacDonald E, Blencowe P, Baker J, Bennett C, Boyd S, Fowler K, Rigoreau L, Stanway E, Watson M, Mao H, Gao H, Zhao C , Zhang Z, Abas H, Org. Lett. 2024, 26, 33, 7043–7048.
Susan Boyd’s work with Astex on the design of engineered crystallographic constructs of CDK7 is now available online.
It is now 20 years since the original (sole trader) CompChem Solutions was founded! It’s been quite a ride. In this time we have co-authored numerous papers, been cited as co-inventors on 5 patent applications and have contributed to the discovery and development of two compounds which are now in the clinic. We became an incorporated company back in 2014 and have worked with dozens of organisations during our 20 years of trading, including big pharma, smaller biotechs, charities, not-for-profit organisations, CROs and academics, in locations ranging from the UK to USA, Europe and the middle east.
We’ve worked in oncology, inflammation, infectious diseases, cardiovascular and many other areas, and have recently become more involved in computational modelling of biological targets as well as assisting with regulatory submissions for small molecules and biologics.
It’s been great fun working with such a diverse portfolio of targets, applications and of course, clients, and we look forward to continuing to provide top quality computational services across the drug discovery spectrum for years to come!
Big thank you to Professor Bobby Glen (now Professor Emeritus at Cambridge) in the picture for helping us celebrate our 10-year anniversary back in 2014!
